Directorate Change

RNS Number : 3223L
Advanced Medical Solutions Grp PLC
12 January 2021


12 January 2021

  Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

  Directorate Changes

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, is pleased to announce that, as the next step in its communicated plan to refresh the Non-Executive Directors on the Board, Grahame Cook is appointed as a Non-Executive Director with effect from 1 February 2021.

 

In line with this plan, Steve Bellamy, who has been an AMS Board member since 2007, will retire from the Board at the next AGM.

 

Grahame has extensive experience as an Executive and Non-Executive Director in a wide range of public and private organisations. He is a chartered accountant and was an investment banker for 18 years, focusing on global equity capital markets, M&A and corporate advisory. For the past 18 years, he has been a Non-Executive Director, most recently on the Boards of Horizon Discovery plc and Morphogenesis Inc, and Chairman of Sinclair Pharma plc.

 

Peter Allen, Chairman of AMS, said: “I am delighted to welcome Grahame to the Board of AMS. Grahame brings significant financial experience and knowledge of the healthcare sector. His experience of driving significant value creation at a number of healthcare companies will be invaluable in the next stage of AMS’s growth. He will make a valuable contribution to our Board. Separately, the Board would like to thank Steve for his significant contribution to the success of AMS over the past fourteen years.

 

Grahame Cook commented: “I have known and admired AMS’s business for many years and am proud to be able to join the team. I look forward to working with the Board to execute on its strategy and build on its strong position in the surgical and woundcare markets.”

 

Grahame will immediately join the Audit, Nomination and Remuneration Committees. The composition of each of the Board Committees from 1 February 2021 is therefore confirmed as follows:

 

Board Committee

Membership

Audit Committee

Steve Bellamy (Chairman)

Grahame Cook

Penny Freer

Nomination Committee

Peter Allen (Chairman)

Steve Bellamy

Grahame Cook

Penny Freer

Chris Meredith

Remuneration Committee

Penny Freer (Chairman)

Peter Allen

Steve Bellamy

Grahame Cook

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Grahame David Cook (age 62) holds or has held directorships and partnerships in the five years preceding his appointment at AMS as follows:

 

Current Directorships

Previous Directorships

Draper Esprit Plc

Horizon Discovery plc

Attraqt plc

Morphogenesis Inc

Sapience Communications Ltd

Sinclair Pharma plc

Pirtsemit Limited

MDY Healthcare plc

T and JK Estates LLP

Actinopharma Limited

TJK Holdings LLP

Crawford Healthcare Holdings Limited

Minoan Group plc

EPI-V GP Investments LLP

KS Halkins LLP


 

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

-End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

 

AMS’s products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUQAGUPGPPG